{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T05:30:44Z","timestamp":1772861444996,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"17","license":[{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s40265-019-01213-x","type":"journal-article","created":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T22:23:13Z","timestamp":1572474193000},"page":"1877-1884","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Dapagliflozin: A Review in Type 1 Diabetes"],"prefix":"10.1007","volume":"79","author":[{"given":"Julia","family":"Paik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah A.","family":"Blair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,29]]},"reference":[{"key":"1213_CR1","unstructured":"National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management. 2016. https:\/\/www.nice.org.uk\/guidance\/ng17 . Accessed 27 Sep 2019."},{"issue":"1","key":"1213_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2337\/cd18-0105","volume":"37","author":"American Diabetes Association","year":"2019","unstructured":"American Diabetes Association. Standards of Medical Care in Diabetes: 2019 abridged for primary care providers. Clin Diabetes. 2019;37(1):11\u201334.","journal-title":"Clin Diabetes."},{"issue":"6","key":"1213_CR3","doi-asserted-by":"publisher","first-page":"971","DOI":"10.2337\/dc15-0078","volume":"38","author":"Kellee M. Miller","year":"2015","unstructured":"Miller KM, Foster NC, Beck RW, et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care. 2015;38(6):971\u20138.","journal-title":"Diabetes Care"},{"issue":"2","key":"1213_CR4","doi-asserted-by":"publisher","first-page":"220","DOI":"10.4158\/EP15869.RA","volume":"22","author":"BW Bode","year":"2016","unstructured":"Bode BW, Garg SK. The emerging role of adjunctive noninsulin antihyperglycemic therapy in the management of type 1 diabetes. Endocr Pract. 2016;22(2):220\u201330.","journal-title":"Endocr Pract."},{"issue":"8","key":"1213_CR5","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.2337\/dc15-0279","volume":"38","author":"International Hypoglycaemia Study Group","year":"2015","unstructured":"International Hypoglycaemia Study Group. Minimizing hypoglycaemia in diabetes. Diabetes Care. 2015;38(8):1583\u201391.","journal-title":"Diabetes Care"},{"issue":"12","key":"1213_CR6","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1007\/s00125-007-0820-z","volume":"50","author":"ES Kilpatrick","year":"2007","unstructured":"Kilpatrick ES, Rigby AS, Goode K, et al. Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia. 2007;50(12):2553\u201361.","journal-title":"Diabetologia"},{"issue":"1","key":"1213_CR7","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s13300-017-0333-9","volume":"9","author":"G Priya","year":"2018","unstructured":"Priya G, Kalra S. A review of insulin resistance in type 1 diabetes: is there a place for adjunctive metformin? Diabetes Ther. 2018;9(1):349\u201361.","journal-title":"Diabetes Ther."},{"issue":"9","key":"1213_CR8","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1177\/1060028017710481","volume":"51","author":"N Ahmed-Sarwar","year":"2017","unstructured":"Ahmed-Sarwar N, Nagel AK, Leistman S, et al. SGLT-2 inhibitors: is there a role in type 1 diabetes mellitus management? Ann Pharmacother. 2017;51(9):791\u20136.","journal-title":"Ann Pharmacother"},{"key":"1213_CR9","doi-asserted-by":"publisher","first-page":"44128","DOI":"10.1038\/srep44128","volume":"7","author":"J Chen","year":"2017","unstructured":"Chen J, Fan F, Wang JY, et al. The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis. Sci Rep. 2017;7:44128.","journal-title":"Sci Rep."},{"issue":"5","key":"1213_CR10","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1007\/s13300-019-00686-z","volume":"10","author":"DK Patel","year":"2019","unstructured":"Patel DK, Strong J. The pleiotropic effects of sodium-glucose cotransporter-2 inhibitors: beyond the glycemic benefit. Diabetes Ther. 2019;10(5):1771\u201392.","journal-title":"Diabetes Ther."},{"key":"1213_CR11","unstructured":"European Medicines Agency. Dapagliflozin (Edistride): summary of product characteristics. 2019. http:\/\/ec.europa.eu\/ . Accessed 27 Sep 2019."},{"issue":"18","key":"1213_CR12","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1007\/s40265-014-0324-3","volume":"74","author":"GL Plosker","year":"2014","unstructured":"Plosker GL. Dapagliflozin: a review of its use in patients with type 2 diabetes. Drugs. 2014;74(18):2191\u2013209.","journal-title":"Drugs."},{"issue":"10","key":"1213_CR13","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40265-019-01148-3","volume":"79","author":"S Dhillon","year":"2019","unstructured":"Dhillon S. Dapagliflozin: a review in type 2 diabetes. Drugs. 2019;79(10):1135\u201346.","journal-title":"Drugs."},{"issue":"11","key":"1213_CR14","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/S2213-8587(17)30308-X","volume":"5","author":"P Dandona","year":"2017","unstructured":"Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(11):864\u201376.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"9","key":"1213_CR15","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.2337\/dc18-0623","volume":"41","author":"C Mathieu","year":"2018","unstructured":"Mathieu C, Dandona P, Gillard P, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial. Diabetes Care. 2018;41(9):1938\u201346.","journal-title":"Diabetes Care"},{"key":"1213_CR16","doi-asserted-by":"crossref","unstructured":"Mathieu C, Dandona P, Philip M, et al. Analysis of benefit\/risk in the subgroup of patients with BMI of\u2009\u2265\u200927 kg\/m2 in the dapagliflozin DEPICT-1 and -2 trials in type 1 diabetes [abstract no. SAT-LB025]. In: Endocrine Society Annual Meeting. 2019.","DOI":"10.1210\/js.2019-SAT-LB025"},{"key":"1213_CR17","unstructured":"European Medicines Agency. Dapagliflozin (Forxiga\/Edistride): public assessment report. 2019. https:\/\/www.ema.europa.eu\/ . Accessed 27 Sep 2019."},{"issue":"12","key":"1213_CR18","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.2337\/dc18-1087","volume":"41","author":"P Dandona","year":"2018","unstructured":"Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study. Diabetes Care. 2018;41(12):2552\u20139.","journal-title":"Diabetes Care"},{"key":"1213_CR19","unstructured":"Rudofsky G, Mathieu C, Dandona P, et al. Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type I diabetes: the DEPICT-2 study [abstract]. In: International Congress of Endocrinology. 2018."},{"key":"1213_CR20","unstructured":"Dandona P, Thoren F, Langkilde AM, et al. Pooled data analysis of composite endpoints from the DEPICT-1 and DEPICT-2 studies using dapagliflozin compared to placebo added to adjustable insulin in type 1 diabetes [abstract no. 612]. Diabetologia. 2018;61 (Suppl 1):S296."},{"issue":"Supplement 1","key":"1213_CR21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2337\/db18-125-LB","volume":"67","author":"CHANTAL MATHIEU","year":"2018","unstructured":"Mathieu C, Dandona P, Phillip M, et al. Glucose variables in T1D studies with dapagliflozin: pooled analysis of continuous glucose monitoring data from DEPICT-1 and 2 [abstract no. 125-LB plus poster]. Diabetes. 2018;67(Suppl 1):LB35.","journal-title":"Diabetes"},{"issue":"6","key":"1213_CR22","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.2337\/dc18-1983","volume":"42","author":"C Mathieu","year":"2019","unstructured":"Mathieu C, Dandona P, Philip M, et al. Glucose variables in type 1 diabetes studies with dapagliflozin: pooled analysis of continuous glucose monitoring data from DEPICT-1 and -2. Diabetes Care. 2019;42(6):1081\u20137.","journal-title":"Diabetes Care"},{"key":"1213_CR23","unstructured":"Handelsman Y, Dandona P, Mathieu C, et al. Dapagliflozin treatment reduces glycemic variability as assessed by standard deviation of interstitial glucose [abstract no. 32 plus poster]. In: AACE 28th Annual Congress. 2019."},{"key":"1213_CR24","doi-asserted-by":"crossref","unstructured":"Gordon J, Danne T, Beresford-Hulme LM, et al. Discontinuation of dapagliflozin in DEPICT-1 and DEPICT-2 led to clinically meaningful increases in HbA1c and body weight [abstract no. 2355-PUB]. In: ADA 79th Scientific Sessions. 2019.","DOI":"10.2337\/db19-2355-PUB"},{"issue":"Supplement 1","key":"1213_CR25","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.2337\/db19-1231-P","volume":"68","author":"PARESH DANDONA","year":"2019","unstructured":"Dandona P, Mathieu C, Phillip M, et al. Dapagliflozin (DAPA) in type 1 diabetes (T1D): pooled outcomes from DEPICT-1 and -2 [abstract no. 1231-P plus poster]. Diabetes. 2019;68(Suppl 1).","journal-title":"Diabetes"},{"key":"1213_CR26","unstructured":"Rudofsky G. Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-2 study. Oral presentation (International Congress of Endocrinology). 2018."},{"key":"1213_CR27","unstructured":"Edelman S, Jendle J, Dandona P, et al. Effect of adding dapagliflozin as an adjunct to insulin on urinary albumin-to-creatinine ratio over 52 weeks in adults with type 1 diabetes [abstract no. TH-PO1156 plus poster]. In: ASN Kidney Week. 2018."},{"issue":"6","key":"1213_CR28","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.2337\/dc18-2316","volume":"42","author":"T Danne","year":"2019","unstructured":"Danne T, Garg S, Peters AL, et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care. 2019;42(6):1147\u201354.","journal-title":"Diabetes Care"},{"key":"1213_CR29","doi-asserted-by":"crossref","unstructured":"Mathieu C, Dandona P, Phillip M, et al. Analysis of benefit:risk in the subgroup of patients with a BMI of\u2009\u2265\u200927 kg\/m2 in the dapagliflozin DEPICT-1 and -2 trials in type 1 diabetes [abstract no. 7914 plus poster]. In: Endocrine Society Annual Meeting. 2019.","DOI":"10.1210\/js.2019-SAT-LB025"},{"issue":"Suppl 1","key":"1213_CR30","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.2337\/dc19-S002","volume":"42","author":"American Diabetes Association","year":"2019","unstructured":"American Diabetes Association. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes. Diabetes Care. 2019;42(Suppl 1):S13\u201328.","journal-title":"Diabetes Care"},{"issue":"3","key":"1213_CR31","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2174\/1573399812666160413115655","volume":"13","author":"F Mittermayer","year":"2017","unstructured":"Mittermayer F, Caveney E, De Oliveira C, et al. Addressing unmet medical needs in type 1 diabetes: a review of drugs under development. Curr Diabetes Rev. 2017;13(3):300\u201314.","journal-title":"Curr Diabetes Rev"},{"issue":"5","key":"1213_CR32","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s13300-019-00680-5","volume":"10","author":"T Nagahisa","year":"2019","unstructured":"Nagahisa T, Saisho Y. Cardiorenal protection: potential of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes. Diabetes Ther. 2019;10(5):1733\u201352.","journal-title":"Diabetes Ther."},{"issue":"10","key":"1213_CR33","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1007\/s00125-018-4671-6","volume":"61","author":"RJ McCrimmon","year":"2018","unstructured":"McCrimmon RJ, Henry RR. SGLT inhibitor adjunct therapy in type 1 diabetes. Diabetologia. 2018;61(10):2126\u201333.","journal-title":"Diabetologia"},{"issue":"9","key":"1213_CR34","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s40265-019-01146-5","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham A, Keam SJ. Sotagliflozin: first global approval. Drugs. 2019;79(9):1023\u20139.","journal-title":"Drugs."},{"key":"1213_CR35","unstructured":"AstraZeneca. Update on US regulatory decision for Farxiga in type-1 diabetes [media release]. 15 Jul 2019. https:\/\/www.astrazeneca.com\/ ."},{"key":"1213_CR36","unstructured":"Lexicon Pharmaceuticals. FDA issues complete response letter for Zynquista (sotagliflozin) [media release]. 22 Mar 2019. http:\/\/www.lexpharma.com ."},{"issue":"4","key":"1213_CR37","doi-asserted-by":"publisher","first-page":"273","DOI":"10.4093\/dmj.2015.39.4.273","volume":"39","author":"S Suh","year":"2015","unstructured":"Suh S, Kim JH. Glycemic variability: how do we measure it and why is it important? Diabetes Metab J. 2015;39(4):273\u201382.","journal-title":"Diabetes Metab J."},{"issue":"3","key":"1213_CR38","doi-asserted-by":"publisher","first-page":"400","DOI":"10.2337\/dc18-1444","volume":"42","author":"RW Beck","year":"2019","unstructured":"Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care. 2019;42(3):400\u20135.","journal-title":"Diabetes Care"},{"issue":"2","key":"1213_CR39","doi-asserted-by":"publisher","first-page":"112","DOI":"10.2337\/cd17-0094","volume":"36","author":"AS Runge","year":"2018","unstructured":"Runge AS, Kennedy L, Brown AS, et al. Does time-in-range matter? Perspectives from people with diabetes on the success of current therapies and the drivers of improved outcomes. Clin Diabetes. 2018;36(2):112\u20139.","journal-title":"Clin Diabetes."},{"key":"1213_CR40","unstructured":"National Institute for Health and Care Excellence. Dapagliflozin with insulin for treating type 1 diabetes: final appraisal document. 2019. https:\/\/www.nice.org\/uk . Accessed 27 Sep 2019."},{"key":"1213_CR41","doi-asserted-by":"crossref","unstructured":"Bennett H, McEwan P, Evans M, et al. Cost-effectiveness of dapagliflozin in adult patients with inadequately controlled type 1 diabetes: a health economic analysis using 24-week results from the DEPICT-1 randomised controlled trial [abstract no. DB4]. Value Health. 2018;21(Suppl 3):S7.","DOI":"10.1016\/j.jval.2018.09.040"},{"issue":"3","key":"1213_CR42","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/dom.12594","volume":"18","author":"W Tang","year":"2016","unstructured":"Tang W, Leil TA, Johnsson E, et al. Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus. Diabetes Obes Metab. 2016;18(3):236\u201340.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1213_CR43","doi-asserted-by":"publisher","first-page":"412","DOI":"10.2337\/dc13-2955","volume":"38","author":"RR Henry","year":"2015","unstructured":"Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 2015;38(3):412\u20139.","journal-title":"Diabetes Care"}],"updated-by":[{"DOI":"10.1007\/s40265-019-01238-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01213-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-01213-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01213-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T12:10:46Z","timestamp":1611663046000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-01213-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,29]]},"references-count":43,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["1213"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01213-x","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40265-019-01238-2","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,29]]},"assertion":[{"value":"29 October 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2019","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article Dapagliflozin: A Review in Type 1 Diabetes, written by Julia Paik and Hannah A. Blair, was originally published Online First without Open Access.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Julia Paik and Hannah Blair are salaried employees of Adis International Ltd\/Springer Nature, are responsible for the article content and declare no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}